Asset Details
Do you wish to reserve the book?
Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?
Do you wish to request the book?
Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?
2022
Overview
The occurrence and development of rheumatoid arthritis (RA) is regulated by numerous cytokines. Interleukin 27 (IL-27) is a soluble cytokine that exerts biological effects by regulating the Janus tyrosine kinase (JAK)/signal transducer and activator of the transcription (STAT) signaling pathway via the IL-27 receptor. IL-27 is known for its pleiotropic roles in modulating inflammatory responses. Previous studies found that IL-27 levels are elevated in RA blood, synovial fluid, and rheumatoid nodules. Cellular and animal experiments indicated that IL-27 exerts multiple regulatory functions in RA patients via different mechanisms. IL-27 inhibits ectopic-like structure (ELS) formation and CD4 + T helper type 2 (Th2) cell, CD4 + T helper type 17 (Th17) cell, and osteoclast differentiation in RA, contributing to alleviating RA. However, IL-27 promotes Th1 cell differentiation, which may exacerbate RA synovitis. Moreover, IL-27 also acts on RA synovial fibroblasts (RA-FLSs) and regulatory T cells (Tregs), but some of its functions are unclear. There is currently insufficient evidence to determine whether IL-27 promotes or relieves RA. Targeting IL-27 signaling in RA treatment should be deliberate based on current knowledge.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
Arthritis, Rheumatoid - immunology
/ Arthritis, Rheumatoid - pathology
/ Cell Differentiation - immunology
/ Disease
/ ectopic-like structure (ELS)
/ Humans
/ Kinases
/ Proteins
/ Synovial Membrane - immunology
/ Synovial Membrane - pathology
/ T-Lymphocytes, Helper-Inducer - immunology
